Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAU 2026 | Emergence of intravesical therapies in bladder cancer

Eva Compérat • 14 Mar 2026
EAU 2026
Bladder Cancer Genitourinary Cancer erda-iDRS HIVEC N-803 TAR-200

Eva Compérat, MD, PhD, Medical University of Vienna, Vienna, Austria, discusses the emergence of new approaches in intravesical therapies, including various BCG plus treatments and other novel therapies such as HIVEC, TAR-200, and TAR-210, as well as treatments involving interleukin-15, like N-803. Prof. Compérat notes that while the follow-up periods for these new trials are short, making it difficult to determine their efficacy compared to BCG, some of these novel treatments may prove to be effective and remain in use. This interview took place at the 41st Annual EAU Congress in London, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Eva Compérat

Molecular testing in prostate cancer: patient selection & urologist-pathologist communication
1:22
Molecular testing in prostate cancer: patient selection & urologist-pathologist communication
Eva Compérat • 14 Mar 2026
Pathology workforce challenges: the need for skilled lab personnel in urothelial cancer diagnostics
0:38
Pathology workforce challenges: the need for skilled lab personnel in urothelial cancer diagnostics
Eva Compérat • 14 Mar 2026
Diagnostic challenges in urinary tract diseases: cytology, biopsy, and Lynch syndrome testing
1:01
Diagnostic challenges in urinary tract diseases: cytology, biopsy, and Lynch syndrome testing
Eva Compérat • 14 Mar 2026
Challenges in classifying bladder tumors: insights on heterogeneity and precision
5:03
Challenges in classifying bladder tumors: insights on heterogeneity and precision
Eva Compérat • 21 Nov 2023

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026
The content of VJOncology is intended for healthcare professionals